Clinigen Group plc Total Voting Rights (3136F)
31 October 2018 - 8:00PM
UK Regulatory
TIDMCLIN
RNS Number : 3136F
Clinigen Group plc
31 October 2018
31 October 2018
Clinigen Group plc
("Clinigen" or the "Group")
Total Voting Rights and Capital
In conformity with Rule 5.6.1 of the Disclosure Guidance and
Transparency Rules, the Group notifies the market that as at 31
October 2018, Clinigen's issued share capital consists of
132,191,498 ordinary shares of 0.1 pence each with voting rights.
No shares are held in Treasury.
The above figure of 132,191,498 may be used by shareholders as
the denominator to determine if they are required to notify their
interests in, or a change to their interests in, the Group under
the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
Shaun Chilton, Group Chief Executive
Officer
Martin Abell, Group Chief Financial
Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black / Tom Ballard (Corporate
Broking)
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653
4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457
2020
Melanie Toyne-Sewell / Alex Shaw /
Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. Clinigen acquired Quantum Pharma in
November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRFMMZGRVMGRZG
(END) Dow Jones Newswires
October 31, 2018 05:00 ET (09:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Clinigen Group Plc (London Stock Exchange): 0 recent articles
More Clinigen Group News Articles